mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern

Emerg Microbes Infect. 2022 Dec;11(1):1550-1553. doi: 10.1080/22221751.2022.2081616.

Abstract

In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.

Keywords: Beta; COVID-19; Omicron; mRNA; vaccine.

Publication types

  • Letter

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19* / prevention & control
  • Humans
  • RNA, Messenger / genetics
  • SARS-CoV-2* / genetics
  • Vaccines, Synthetic
  • mRNA Vaccines

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • RNA, Messenger
  • Vaccines, Synthetic
  • mRNA Vaccines
  • BNT162 Vaccine

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This work was supported by a grant from National Key R&D Program of China [No. 2021YFC2301700].